Standout Papers

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropan... 2024 202686
  1. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024)
    Simron Singh, Daniel Halperin et al. The Lancet

Immediate Impact

2 from Science/Nature 57 standout
Sub-graph 1 of 24

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
2 intermediate papers

Works of Beth Chasen being referenced

<p>Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients</p>
2020
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
2014

Author Peers

Author Last Decade Papers Cites
Beth Chasen 268 185 120 159 35 528
Pierpaolo Pattacini 123 90 50 205 47 609
G Aliberti 240 217 110 116 50 636
Prakash Manoharan 332 137 59 64 41 571
Jordan A. Torok 146 77 31 127 29 529
J. L. G. Blaauwgeers 186 151 213 48 31 637
F. Vorbeck 220 209 126 141 29 569
Samuel Jang 217 82 39 144 33 640
Serap Akyürek 129 143 96 135 47 599
Daishu Miura 263 132 85 51 38 577
Christian Stremmel 216 58 43 92 25 632

All Works

Loading papers...

Rankless by CCL
2026